Zobrazeno 1 - 10
of 170
pro vyhledávání: '"Teng Moua"'
Autor:
Tananchai Petnak, Wisit Cheungpasitporn, Charat Thongprayoon, Tulaton Sodsri, Supawit Tangpanithandee, Teng Moua
Publikováno v:
Respiratory Research, Vol 25, Iss 1, Pp 1-10 (2024)
Abstract Background Patients with fibrotic hypersensitivity pneumonitis (f-HP) have varied clinical and radiologic presentations whose associated phenotypic outcomes have not been previously described. We conducted a study to evaluate mortality and l
Externí odkaz:
https://doaj.org/article/aca78efe1a244a92a68a0cf44b0b596d
Autor:
Franck F. Rahaghi, Vivien M. Hsu, Robert J. Kaner, Maureen D. Mayes, Ivan O. Rosas, Rajan Saggar, Virginia D. Steen, Mary E. Strek, Elana J. Bernstein, Nitin Bhatt, Flavia V. Castelino, Lorinda Chung, Robyn T. Domsic, Kevin R. Flaherty, Nishant Gupta, Bashar Kahaleh, Fernando J. Martinez, Lee E. Morrow, Teng Moua, Nina Patel, Oksana A. Shlobin, Brian D. Southern, Elizabeth R. Volkmann, Dinesh Khanna
Publikováno v:
Respiratory Research, Vol 24, Iss 1, Pp 1-16 (2023)
Abstract Background Systemic sclerosis (SSc) is a rare, complex, connective tissue disorder. Interstitial lung disease (ILD) is common in SSc, occurring in 35–52% of patients and accounting for 20–40% of mortality. Evolution of therapeutic option
Externí odkaz:
https://doaj.org/article/f0f7c08666254d739a6ca421ab557bf3
Autor:
Yuanchen Zhao, Yang Gao, Tananchai Petnak, Wisit Cheungpasitporn, Charat Thongprayoon, Xing Zhang, Teng Moua
Publikováno v:
Respiratory Research, Vol 23, Iss 1, Pp 1-14 (2022)
Abstract Background Rituximab (RTX) has been previously reported as directed treatment in patients with connective-tissue disease-related interstitial lung diseases (CTD-ILD). A systematic assessment of treatment effect size on pulmonary function out
Externí odkaz:
https://doaj.org/article/d27d9bb123ab493489a8fb6dd2198e46
Publikováno v:
BMC Pulmonary Medicine, Vol 22, Iss 1, Pp 1-9 (2022)
Abstract Background Recent studies support the diagnostic role of bronchoalveolar lavage lymphocytosis (BALL) in patients with suspected hypersensitivity pneumonitis (HP). Our study aim was to determine the spectrum of BALL findings with elimination
Externí odkaz:
https://doaj.org/article/a2f6c2dea9584447a34a502c92614932
Autor:
Angsupat Pornchai, Teng Moua
Publikováno v:
Respiratory Medicine Case Reports, Vol 43, Iss , Pp 101839- (2023)
Light chain deposition disease (LCDD) is a rare hematologic disorder characterized by non-amyloid monoclonal immunoglobulin light chain deposition in multiple organs. Pulmonary LCDD (PLCDD) is an uncommon manifestation of LCDD usually seen in middle-
Externí odkaz:
https://doaj.org/article/f84b64c86b444700a5a225262d859330
Autor:
Bryan T. Kelly, Viengneesee Thao, Timothy M. Dempsey, Lindsey R. Sangaralingham, Stephanie R. Payne, Taylor T. Teague, Teng Moua, Nilay D. Shah, Andrew H. Limper
Publikováno v:
BMC Pulmonary Medicine, Vol 21, Iss 1, Pp 1-14 (2021)
Abstract Background Idiopathic Pulmonary Fibrosis is a chronic, progressive interstitial lung disease for which there is no cure. However, lung function decline, hospitalizations, and mortality may be reduced with the use of the antifibrotic medicati
Externí odkaz:
https://doaj.org/article/510e1e63fe4a474d9de59209fad2fdef
Autor:
Flavia V. Castelino, Teng Moua
Publikováno v:
ACR Open Rheumatology, Vol 3, Iss 5, Pp 295-304 (2021)
Interstitial lung disease (ILD) is a common manifestation of connective tissue diseases (CTDs). A proportion of patients with CTD‐ILDs develop progressive fibrosing ILD, which is characterized by worsening fibrotic abnormalities on high‐resolutio
Externí odkaz:
https://doaj.org/article/0b728c7050034ef79c5af6b676808b44
Autor:
Marlies Wijsenbeek, Maria Molina-Molina, Olivier Chassany, John Fox, Liam Galvin, Klaus Geissler, Katherine M. Hammitt, Michael Kreuter, Teng Moua, Emily C. O'Brien, Ashley F. Slagle, Anna Krasnow, Matthew Reaney, Michael Baldwin, Natalia Male, Klaus B. Rohr, Jeff Swigris, Katerina Antoniou
Publikováno v:
ERJ Open Research, Vol 8, Iss 2 (2022)
Background An understanding of the experience of patients with progressive fibrosing interstitial lung disease (PF-ILD) is needed to select appropriate patient-reported outcome measures (PROMs) to evaluate treatment effect in clinical trials. Methods
Externí odkaz:
https://doaj.org/article/2b4d0656e26e4705841c755f6e5ab14a
Autor:
Matthew Koslow, MD, Eric S. Edell, MD, David E. Midthun, MD, John J. Mullon, MD, Ryan M. Kern, MD, Darlene R. Nelson, MD, Kenneth K. Sakata, MD, Teng Moua, MD, Anja C. Roden, MD, Eunhee S. Yi, MD, Janani S. Reisenauer, MD, Paul A. Decker, MS, Jay H. Ryu, MD
Publikováno v:
Mayo Clinic Proceedings: Innovations, Quality & Outcomes, Vol 4, Iss 5, Pp 565-574 (2020)
Objective: To assess the contribution and safety of bronchoscopic cryobiopsy vs traditional forceps biopsy used in clinical practice for diagnosing diffuse parenchymal lung disease (DPLD). Patients and Methods: We identified 271 patients who underwen
Externí odkaz:
https://doaj.org/article/3e0f7c605650409d9b6a2a887a999993
Autor:
Pahnwat Taweesedt, Ploypin Lertjitbanjong, Dararat Eksombatchai, Prangthip Charoenpong, Teng Moua, Charat Thongprayoon, Supawit Tangpanithandee, Tananchai Petnak
Publikováno v:
Journal of Clinical Medicine, Vol 12, Iss 2, p 655 (2023)
Antifibrotic treatment has been approved for reducing disease progression in fibrotic interstitial lung disease (ILD). As a result of increased bleeding risk, some experts suggest cessation of antifibrotics prior to lung transplantation (LT). However
Externí odkaz:
https://doaj.org/article/a867f9640d404568bad0d978abd64f12